11 April 2013
Details
Versalis and Genomatica
announced the signing of a definitive
joint development and licensing agreement to
establish a technology joint venture for
bio-based butadiene.
- The two companies will work together to develop
a complete end-to-end process for
the production of butadiene from
non-food biomass.
- The resulting process will be licensed across
Europe, Asia and Africa
by the newly-created joint venture.
- Future licensees of the process, including Versalis,
will provide the capital required for the
construction and operation of their own plants,
and be responsible for the use and sale of butadiene.
- Versalis will over $20 million in funding to Genomatica
to support development of integrated end-to-end process.
It will also aims to be the first to license the process
and build commercial plants.
- The current agreement completes the steps
included in the Memorandum of Understanding
announced in July 2012.
- The joint venture will leveraget the proven strengths of
both companies.
- Genomatica brings its expertise in biotechnology,
particularly in engineered microorganisms and
fermentation.
- As a leaders in butadiene-based products, Versalis will
brings its long-standing expertise in catalysis and
process engineering that is vital for the development of
bio-based butadiene technologies.
WWW.CHEMWINFO.COM BY KHUN PHICHAI
